Sofinnova Partners

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

GFBiochemicals is a pioneering company that specializes in the production of levulinic acid directly from biomass on a commercial scale. Founded in 2008 by a group of biobased chemical experts, the company aims to revolutionize the chemicals and biofuels market by replacing petroleum-based products with sustainable alternatives. Through partnerships with the University of Pisa and the Polytechnic University of Milan, GFBiochemicals has developed breakthrough production technologies showcased in their Caserta plant. This plant has been equipped with innovative conversion, recovery, and purification technology to support the company's mission of advancing sustainable and eco-friendly solutions in various market sectors.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.

Epsilen Bio Srl is a Milan-based biotechnology company focused on developing innovative therapies for patients with underserved medical conditions. Founded in December 2019, the company specializes in a transformative approach known as epigenetic silencing, which targets and stabilizes the genomic silencing of genes implicated in various pathological processes. By leveraging this platform, Epsilen Bio aims to provide healthcare professionals with new therapeutic options to address significant medical needs.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

Aledia SA, established in 2011, specializes in the development and manufacturing of light-emitting diodes (LEDs). The company's proprietary technology involves a 3D architecture using gallium-nitride-on-silicon microwires, enabling cost-effective production of LED chips at 25% the cost of traditional planar LED chips. Aledia's products cater to general lighting, automotive, and display applications, with a focus on mobile displays and microdisplays for AR/VR devices. Headquartered in Grenoble, France, the company has subsidiaries in Malacca, Malaysia, and Palo Alto, California.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Aledia SA, established in 2011, specializes in the development and manufacturing of light-emitting diodes (LEDs). The company's proprietary technology involves a 3D architecture using gallium-nitride-on-silicon microwires, enabling cost-effective production of LED chips at 25% the cost of traditional planar LED chips. Aledia's products cater to general lighting, automotive, and display applications, with a focus on mobile displays and microdisplays for AR/VR devices. Headquartered in Grenoble, France, the company has subsidiaries in Malacca, Malaysia, and Palo Alto, California.

Twenga, established in 2006, is a London-based online shopping search platform that connects over 4000 clients across 15 countries with a diverse range of products. It offers services including traffic acquisition, price comparison, and international exposure, helping advertisers enhance their performance and automate investments. With over 120 employees across France, Germany, and the UK, Twenga facilitates the discovery of products across categories like fashion, homeware, and sports, enabling users to find and compare products at competitive prices.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.

Aledia SA, established in 2011, specializes in the development and manufacturing of light-emitting diodes (LEDs). The company's proprietary technology involves a 3D architecture using gallium-nitride-on-silicon microwires, enabling cost-effective production of LED chips at 25% the cost of traditional planar LED chips. Aledia's products cater to general lighting, automotive, and display applications, with a focus on mobile displays and microdisplays for AR/VR devices. Headquartered in Grenoble, France, the company has subsidiaries in Malacca, Malaysia, and Palo Alto, California.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

QuesCom S.A., founded in 1999 and headquartered in Sophia Antipolis, France, specializes in designing and manufacturing Internet telecommunication systems. The company offers a range of products including business communication management portals, GSM gateways, SIM servers, and mobile call servers. Its technology encompasses VoIP solutions and network management software, catering to both enterprises and service providers. QuesCom collaborates with established industry partners such as Aastra, Alcatel, Avaya, and Cisco to enhance its offerings and maintain a competitive edge in the telecommunications market.

Sensitive Object SA specializes in the development of electronic products that enhance touch interface technology across various sectors. Founded in 2003 and headquartered in Boulogne Billancourt, France, the company offers solutions for consumer electronics, computing, outdoor interactive applications, home automation, healthcare, industrial control, and digital advertising. Its product range includes touch screens, peripherals, and control panels, catering to diverse industry needs. Sensitive Object also maintains operations in Paris and Singapore, further expanding its reach in the global market.

EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.

Streamezzo S.A. is a company based in Paris, France, specializing in the development of mobile media products and solutions. Founded in 2004, it provides a range of tools that enable telecom operators, broadcasters, media companies, and content providers to create, deploy, and manage services on cellular networks. Its key offerings include the Rich Media Software Suite, which features a Rich Media Client for accessing interactive mobile services, a Rich Media Server for service deployment, and a Workbench for multimedia authoring. Additionally, Streamezzo's solutions encompass Interactive Mobile TV, Music Jukebox for music downloads, and dynamic user interfaces that enhance user engagement. The company also offers professional services to support its clients in effectively utilizing these technologies.

Neosens SA specializes in the design and development of sensor solutions aimed at monitoring and controlling the quality of water and industrial liquids. The company offers advanced sensors that detect dissolved oxygen and systems for continuous fouling monitoring. Its technologies are applied across various sectors, including cooling systems, heat exchangers, potable and ultra-pure water management, as well as in industries such as food and beverage, pharmaceuticals, pulp and paper, and oil and gas. Founded in 2001 and headquartered in Labege, France, Neosens is committed to providing innovative solutions that enhance the efficiency and safety of liquid management in diverse environmental applications.

Qosmos SA, established in 2000 and headquartered in Paris, France, specializes in network intelligence technology. It offers solutions that identify and extract information from network traffic, enabling real-time data activity analysis. Qosmos' key products include ixEngine, a software development kit for DPI-based IP traffic classification, and Qosmos Classifier, a real-time traffic flow classification component. The company serves various applications such as lawful interception, network protection, and regulatory compliance, with a global presence across Europe, the U.S., Japan, and Singapore. Since December 2016, Qosmos operates as a subsidiary of Enea AB.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Neosens SA specializes in the design and development of sensor solutions aimed at monitoring and controlling the quality of water and industrial liquids. The company offers advanced sensors that detect dissolved oxygen and systems for continuous fouling monitoring. Its technologies are applied across various sectors, including cooling systems, heat exchangers, potable and ultra-pure water management, as well as in industries such as food and beverage, pharmaceuticals, pulp and paper, and oil and gas. Founded in 2001 and headquartered in Labege, France, Neosens is committed to providing innovative solutions that enhance the efficiency and safety of liquid management in diverse environmental applications.

Inside Secure, established in 1995 and headquartered in Aix en Provence, France, is a fabless semiconductor company specializing in open-standard contactless payment and near field communication (NFC) solutions. It offers a range of products, including contactless reader interface chips, NFC interface circuits, payment platforms, and memory chips, catering to smart cards, mobile phones, and POS devices. The company also provides professional services such as application development and system integration. Its clients include payment card manufacturers, mobile phone producers, systems integrators, and financial institutions. Additionally, Inside Secure acquired MePIN, a white-label strong authentication platform, expanding its offerings to include secure online identity and payment services.

Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.

Streamezzo S.A. is a company based in Paris, France, specializing in the development of mobile media products and solutions. Founded in 2004, it provides a range of tools that enable telecom operators, broadcasters, media companies, and content providers to create, deploy, and manage services on cellular networks. Its key offerings include the Rich Media Software Suite, which features a Rich Media Client for accessing interactive mobile services, a Rich Media Server for service deployment, and a Workbench for multimedia authoring. Additionally, Streamezzo's solutions encompass Interactive Mobile TV, Music Jukebox for music downloads, and dynamic user interfaces that enhance user engagement. The company also offers professional services to support its clients in effectively utilizing these technologies.

VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.

Purple Labs SA specializes in developing mobile Linux software solutions tailored for real-time operating systems (RTOS) and Linux-based mobile devices. The company offers a comprehensive mobile Linux platform and an application suite specifically designed for 3G feature phones, providing essential tools for phone manufacturers to enhance their product offerings. Their flagship product, Purple Magic, is a 3G Linux feature phone that supports video telephony, music playback, high-speed internet browsing, and video streaming. In addition to software solutions, Purple Labs provides application integration, Linux support package customization, hardware design assistance, and product industrialization services. Founded in 2001 and headquartered in Le Bourget du Lac, France, the company has expanded its presence with offices in several regions, including the United Kingdom, the United States, China, South Korea, Taiwan, and Hong Kong. As of 2009, Purple Labs operates as a subsidiary of Myriad Group AG.

Inside Secure, established in 1995 and headquartered in Aix en Provence, France, is a fabless semiconductor company specializing in open-standard contactless payment and near field communication (NFC) solutions. It offers a range of products, including contactless reader interface chips, NFC interface circuits, payment platforms, and memory chips, catering to smart cards, mobile phones, and POS devices. The company also provides professional services such as application development and system integration. Its clients include payment card manufacturers, mobile phone producers, systems integrators, and financial institutions. Additionally, Inside Secure acquired MePIN, a white-label strong authentication platform, expanding its offerings to include secure online identity and payment services.

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Oxxius SA specializes in the development, design, manufacturing, and sale of diode-pumped solid-state lasers and laser diode modules. Founded in 2002 and headquartered in Lannion, France, the company produces a range of lasers including UV, visible, and infrared options, as well as ultra-stable and single longitudinal mode laser modules. These products serve various applications such as fluorescence analysis in flow cytometry and microscopy, interferometry in laser Doppler velocimetry and holography, and Raman spectroscopy. Oxxius's innovative laser technology offers significant advancements in compactness, reliability, and cost-efficiency, catering to both research and industrial markets. The company distributes its products through a network of partners across multiple countries, ensuring wide accessibility for its offerings in bio-photonics, metrology, and spectroscopy.

Qosmos SA, established in 2000 and headquartered in Paris, France, specializes in network intelligence technology. It offers solutions that identify and extract information from network traffic, enabling real-time data activity analysis. Qosmos' key products include ixEngine, a software development kit for DPI-based IP traffic classification, and Qosmos Classifier, a real-time traffic flow classification component. The company serves various applications such as lawful interception, network protection, and regulatory compliance, with a global presence across Europe, the U.S., Japan, and Singapore. Since December 2016, Qosmos operates as a subsidiary of Enea AB.

Varioptic SA specializes in the design and manufacturing of adjustable lens solutions, particularly focusing on electrically controlled optical liquid lenses. Founded in 2002 and based in Lyon, France, the company provides products such as variable focus liquid lenses, autofocus lens modules, and microscope lenses, which cater to diverse sectors including industrial, biometrics, medical, and consumer applications. Varioptic emphasizes research and development to enhance its technology and innovate new products. The company's offerings are distributed through various channels, and it operates as a subsidiary of Invenios France SAS.

Streamezzo S.A. is a company based in Paris, France, specializing in the development of mobile media products and solutions. Founded in 2004, it provides a range of tools that enable telecom operators, broadcasters, media companies, and content providers to create, deploy, and manage services on cellular networks. Its key offerings include the Rich Media Software Suite, which features a Rich Media Client for accessing interactive mobile services, a Rich Media Server for service deployment, and a Workbench for multimedia authoring. Additionally, Streamezzo's solutions encompass Interactive Mobile TV, Music Jukebox for music downloads, and dynamic user interfaces that enhance user engagement. The company also offers professional services to support its clients in effectively utilizing these technologies.

Fovea Pharmaceuticals is a French biopharmaceutical company based in Paris, specializing in the discovery and development of drugs for ocular diseases. Founded in 2005, the company focuses on addressing various eye conditions, including allergic conjunctivitis, diabetic macular edema, and retinitis pigmentosa. Its product portfolio includes FOV1101 Prednisporin for allergic conjunctivitis, a proprietary plasma kallikrein-kinin inhibitor known as FOV2302 for hereditary angioedema, FOV2304 for diabetic macular edema, and FOV2501, an intravitreal formulation targeting retinitis pigmentosa and potentially dry age-related macular degeneration. As of October 30, 2009, Fovea operates as a subsidiary of Sanofi.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software. With offices in the UK and the US, the company employs over 80 staff and has been serving Fortune 500 clients for more than 15 years. Its flagship product, the Open Print software suite, is designed for sectors such as financial services, banking, insurance, utilities, telecommunications, and the public sector. Open Print enables the design, composition, and production of complex, data-driven B2C documents, allowing organizations to integrate multiple data sources for personalized communications. The software is increasingly utilized to revamp mission-critical documents to align with the latest marketing initiatives, thereby enhancing revenue opportunities. Notable clients in the UK include Nationwide, HBOS, and British Telecom, all of whom have utilized Open Print since the early 2000s.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.

Sensitive Object SA specializes in the development of electronic products that enhance touch interface technology across various sectors. Founded in 2003 and headquartered in Boulogne Billancourt, France, the company offers solutions for consumer electronics, computing, outdoor interactive applications, home automation, healthcare, industrial control, and digital advertising. Its product range includes touch screens, peripherals, and control panels, catering to diverse industry needs. Sensitive Object also maintains operations in Paris and Singapore, further expanding its reach in the global market.

Oxxius SA specializes in the development, design, manufacturing, and sale of diode-pumped solid-state lasers and laser diode modules. Founded in 2002 and headquartered in Lannion, France, the company produces a range of lasers including UV, visible, and infrared options, as well as ultra-stable and single longitudinal mode laser modules. These products serve various applications such as fluorescence analysis in flow cytometry and microscopy, interferometry in laser Doppler velocimetry and holography, and Raman spectroscopy. Oxxius's innovative laser technology offers significant advancements in compactness, reliability, and cost-efficiency, catering to both research and industrial markets. The company distributes its products through a network of partners across multiple countries, ensuring wide accessibility for its offerings in bio-photonics, metrology, and spectroscopy.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Varioptic SA specializes in the design and manufacturing of adjustable lens solutions, particularly focusing on electrically controlled optical liquid lenses. Founded in 2002 and based in Lyon, France, the company provides products such as variable focus liquid lenses, autofocus lens modules, and microscope lenses, which cater to diverse sectors including industrial, biometrics, medical, and consumer applications. Varioptic emphasizes research and development to enhance its technology and innovate new products. The company's offerings are distributed through various channels, and it operates as a subsidiary of Invenios France SAS.

InfraWorlds is an innovative French startup specializing in embedded Java technologies and solutions for wireless phones. Its technological competencies, coupled with unrivalled graphic creativity, have earned the company a solid reputation among the main players in this booming sector. Built around a team of dedicated professionals, which is soon to be expanded, InfraWorlds is today consolidating its lead in the fast-growing global wireless entertainment market.

Varioptic SA specializes in the design and manufacturing of adjustable lens solutions, particularly focusing on electrically controlled optical liquid lenses. Founded in 2002 and based in Lyon, France, the company provides products such as variable focus liquid lenses, autofocus lens modules, and microscope lenses, which cater to diverse sectors including industrial, biometrics, medical, and consumer applications. Varioptic emphasizes research and development to enhance its technology and innovate new products. The company's offerings are distributed through various channels, and it operates as a subsidiary of Invenios France SAS.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.